Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Lennestål, Roland
Publications (2 of 2) Show all publications
Lennestål, R., Otterblad Olausson, P. & Källén, B. (2009). Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. European Journal of Clinical Pharmacology, 65(6), 615-625
Open this publication in new window or tab >>Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants
2009 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 65, no 6, p. 615-625Article in journal (Refereed) Published
Abstract [en]

Purpose To investigate the association between maternal use of antihypertensives in early pregnancy and delivery outcome, notably infant congenital malformations.

Methods A cohort study of 1,418 women who had used antihypertensive drugs in early pregnancy but had no diabetes diagnosis were identified from the Swedish Medical Birth Register.

Results There was an excess risk for placental abruption, caesarean section, delivery induction, and post-delivery hemorrhage in women taking hypertensives. Infants were more often than expected born preterm, were small for gestational age, and had an excess of various neonatal symptoms. Cardiovascular defects occurred with an adjusted odds ratio of 2.59 (95% CI 1.92-3.51). The results were similar when the woman had used ACE inhibitors or other antihypertensives, notably beta blockers. Stillbirth rate was increased (risk ratio 1.87, 95% CI 1.02-3.02), again without any clear drug specificity.

Conclusions There seems to be little drug specificity in the association between maternal use of antihypertensives and an increased risk for infant cardiovascular defects.

Place, publisher, year, edition, pages
Springer, 2009
Keywords
ACE inhibitors, Antihypertensives, Beta-blocking agents, Cardiovascular defects, Congenital malformations, Stillbirths
National Category
Social and Clinical Pharmacy Pharmacology and Toxicology
Identifiers
urn:nbn:se:umu:diva-115998 (URN)10.1007/s00228-009-0620-0 (DOI)000266886000010 ()19198819 (PubMedID)2-s2.0-68849090817 (Scopus ID)
Available from: 2016-02-25 Created: 2016-02-08 Last updated: 2023-03-24Bibliographically approved
Lennestål, R., Lakso, H.-Å., Nilsson, M. & Mjörndal, T. (2008). Urine monitoring of diazepam abuse: new intake or not?. Journal of Analytical Toxicology, 32(6), 402-407
Open this publication in new window or tab >>Urine monitoring of diazepam abuse: new intake or not?
2008 (English)In: Journal of Analytical Toxicology, ISSN 0146-4760, E-ISSN 1945-2403, Vol. 32, no 6, p. 402-407Article in journal (Refereed) Published
Abstract [en]

Testing for drugs-of-abuse in urine is requested for multiple reasons, including legal and workplace policies. Two cases were studied in which there was a suspicion that the patients continued to abuse diazepam, because of repeatedly positive urine samples. In these cases, diazepam metabolites were measured in urine samples by gas or liquid chromatography coupled to mass spectrometry. The concentrations of diazepam metabolites were subsequently creatinine correlated. Very long elimination times were found in the described cases. None of them had in fact ingested diazepam again during the study period. By the use of pharmacogenetic typing, one of the subjects was found to have a slow metabolism for CYP2C9 as well as for CYP2C19. In the second case, there was a possible drug interaction between diazepam and zolpidem.

Keywords
genetic polymorphisms; cytochrome p450s; metabolism; drugs; pharmacokinetics; pharmacogenetics; cyp2c19; creatinine; excretion; obesity
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:umu:diva-26535 (URN)18652745 (PubMedID)
Available from: 2009-10-13 Created: 2009-10-13 Last updated: 2018-06-08Bibliographically approved
Organisations

Search in DiVA

Show all publications